drugset / Trial / NCT02874794

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

NCT02874794

Phase 4 Completed 465 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection fraction \[LVEF\] ≤ 40%) after 12 weeks of treatment. The primary endpoint is the change in aortic characteristic impedance (Zc = dP/dQ in early systole) between baseline and Week 12.

Timeline

Start
2016-08-17
Primary completion
2018-12-13
Completion
2019-01-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enalapril Other / unclassified 2.5 mg Oral
Comparator Enalapril Other / unclassified 5 mg Oral
Comparator Enalapril Other / unclassified 10 mg Oral
Subject sacubitril/valsartan Unknown 24 mg Oral
Subject sacubitril/valsartan Unknown 49 mg Oral
Subject sacubitril/valsartan Unknown 97 mg Oral

Indications